Cargando…

Interleukin-6 signaling blockade treatment for cytokine release syndrome in COVID-19 (Review)

A severe immune response in patients with coronavirus disease 2019 (COVID-19) can cause a potentially lethal unconstrained inflammatory cytokine storm, known as cytokine release syndrome (CRS). The present study provides an overview of the biology underlying CRS and how targeted inhibition of interl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Jia-Jie, Zhang, Li-Na, Hou, Hu, Xu, Lingqing, Ji, Kunmei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7690237/ https://www.ncbi.nlm.nih.gov/pubmed/33262810 http://dx.doi.org/10.3892/etm.2020.9456

Ejemplares similares

Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)?
por: Liu, Bingwen, et al.
Publicado: (2020)

A Cytokine–Cytokine Interaction in the Assembly of Higher-Order Structure and Activation of the Interleukine-3:Receptor Complex
por: Dey, Raja, et al.
Publicado: (2009)

Rethinking interleukin-6 blockade for treatment of COVID-19
por: Scherger, S., et al.
Publicado: (2020)

Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality
por: Zhang, Chi, et al.
Publicado: (2020)

Interleukin Inhibitors in Cytokine Release Syndrome and Neurotoxicity Secondary to CAR-T Therapy
por: Ferreros, Puri, et al.
Publicado: (2022)

The conundrum of interleukin-6 blockade in COVID-19
por: Campochiaro, Corrado, et al.
Publicado: (2020)

The blockade of interleukin‐33 released by hepatectomy would be a promising treatment option for cholangiocarcinoma
por: Nagaoka, Satoshi, et al.
Publicado: (2020)

Less Can Be More When Targeting Interleukin-6-Mediated Cytokine Release Syndrome in Coronavirus Disease 2019
por: Betts, Brian C., et al.
Publicado: (2020)

Role of IL-6 inhibitor in treatment of COVID-19-related cytokine release syndrome
por: Du, Peng, et al.
Publicado: (2021)

Interleukin‐1 blockade treatment decreasing cardiovascular risk
por: Zheng, Zi‐Heng, et al.
Publicado: (2019)

Preemptive interleukin-6 blockade in patients with COVID-19
por: Guillén, Lucía, et al.
Publicado: (2020)

CDK4/6 inhibitor palbociclib suppresses IgE-mediated mast cell activation
por: Hou, Yi-Bo, et al.
Publicado: (2019)

Structural Understanding of Interleukin 6 Family Cytokine Signaling and Targeted Therapies: Focus on Interleukin 11
por: Metcalfe, Riley D., et al.
Publicado: (2020)

Interplay between interleukin-6 signaling and the vascular endothelium in cytokine storms
por: Kang, Sujin, et al.
Publicado: (2021)

Confronting the controversy: interleukin-6 and the COVID-19 cytokine storm syndrome
por: Chen, Luke Y.C., et al.
Publicado: (2020)

Soluble interleukin-6 receptor in the COVID-19 cytokine storm syndrome
por: Chen, Luke Y.C., et al.
Publicado: (2021)

Interleukin-6 Blockade With Tocilizumab in Anakinra-Refractory Febrile Infection-Related Epilepsy Syndrome (FIRES)
por: Stredny, Coral M., et al.
Publicado: (2020)

Cytokine release syndrome
por: Shimabukuro-Vornhagen, Alexander, et al.
Publicado: (2018)

Role of Interleukin-6 Family Cytokines in Organ Fibrosis
por: Chen, Ying, et al.
Publicado: (2023)

Jak-Stat Signaling Induced by Interleukin-6 Family Cytokines in Hepatocellular Carcinoma
por: Lokau, Juliane, et al.
Publicado: (2019)

Interleukin-6 Antagonist Tocilizumab to Treat Critically Ill Coronavirus Disease 2019 Patients With Cytokine Release Syndrome: A Case Series
por: Yang, Stephen Su, et al.
Publicado: (2021)

Selective Interleukin-6 Trans-Signaling Blockade Is More Effective Than Panantagonism in Reperfused Myocardial Infarction
por: George, Marc Jonathan, et al.
Publicado: (2021)

Interleukin-6: discovery of a pleiotropic cytokine
por: Kishimoto, Tadamitsu
Publicado: (2006)

Historical overview of the interleukin-6 family cytokine
por: Kang, Sujin, et al.
Publicado: (2020)

Interleukin 1 blockade withcanakinumab for Hyper IGD syndrome (HIDS)
por: Brunnner, J, et al.
Publicado: (2015)

Functional and Morphological Improvement of Dystrophic Muscle by Interleukin 6 Receptor Blockade
por: Pelosi, Laura, et al.
Publicado: (2015)

Rituximab and Cytokine Release Syndrome
por: Kulkarni, Hrishikesh S., et al.
Publicado: (2012)

Use of the interleukin 6 inhibitor tocilizumab in Japanese patients with cytokine release syndrome caused by COVID-19-related acute respiratory distress syndrome: A case series
por: Nakamura, Hideta, et al.
Publicado: (2020)

Sex and interleukin-6 are prognostic factors for autoimmune toxicity following treatment with anti-CTLA4 blockade
por: Valpione, Sara, et al.
Publicado: (2018)

Interleukin 1 blockade with canacinumab for hyperimmunoglobulin D and periodic fever syndrome
por: Brunner, Juergen, et al.
Publicado: (2014)

Correction: Historical overview of the interleukin-6 family cytokine
por: Kang, Sujin, et al.
Publicado: (2020)

Interleukin-6 Perpetrator of the COVID-19 Cytokine Storm
por: Shekhawat, Jyoti, et al.
Publicado: (2021)

Serum levels of interleukin-6 type cytokines and soluble interleukin-6 receptor in patients with rheumatoid arthritis.
por: Robak, T, et al.
Publicado: (1998)

SOCS3: An essential physiological inhibitor of signaling by interleukin-6 and G-CSF family cytokines
por: White, Christine A, et al.
Publicado: (2013)

Utilizing tocilizumab for the treatment of cytokine release syndrome in COVID-19
por: Hassoun, Ali, et al.
Publicado: (2020)

Emapalumab for the treatment of refractory cytokine release syndrome in pediatric patients
por: Schuelke, Matthew R., et al.
Publicado: (2023)

Inflammasome signaling and regulation of interleukin-1 family cytokines
por: Chan, Amy H., et al.
Publicado: (2019)

Cytokine Release Syndrome: Current Perspectives
por: Murthy, Hemant, et al.
Publicado: (2019)

Implications of Interleukin-6 (IL-6)-blockade for severe COVID-19 infection in patients with Multiple Myeloma
por: Sgherza, Nicola, et al.
Publicado: (2021)

Targeting JAK-STAT Signaling to Control Cytokine Release Syndrome in COVID-19
por: Luo, Wei, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_p9kafjb2d7fmktvm0fimpuqsq5